Valeria Santini

Featured in: Favicon

nature.com Favicon

wiley.com

thelancet.com Favicon

onclive.com Favicon

emjreviews.com Favicon

oncologytube.com Favicon

onlinelibrary.wiley.com

Articles

Luspatercept ESA in LR-MDSPhase 3 MEDALIST Study

Dec 13, 2023 | oncologytube.com | Valeria Santini

If you can't view this video, your browser does not support HTML5 videos To view this video please enable JavaScript, and consider upgrading to a web browser thatsupports HTML5 video Dr. Valeria Santini discusses the Phase 3 Medalist study at ASH 2023, highlighting Luspatercept's efficacy in lower-risk myelodysplastic syndromes, providing transfusion independence benefits over an extended period 1 day 0 Views Category: Description: By. Valeria Santini, MD Date: 12/13/2023 At the ASH 2023...
Unmet Needs and Future of Lower-Risk MDS

Oct 19, 2023 | onclive.com | Uwe Platzbecker |Rami D. Komrokji |Valeria Santini

Unmet Needs and Future of Lower-Risk MDSThe panel concludes their discussion with a look toward the future of lower-risk myelodysplastic syndrome treatment and the unmet needs that should be addressed.
Treatment Strategies and Sequencing in MDS

Oct 12, 2023 | onclive.com | Uwe Platzbecker |Rami D. Komrokji |Valeria Santini

Rami Komrokji, MD, provides clinical insights on treatment decision-making, sequencing, and combinations for patients with myelodysplastic syndrome. Please note: Since the filming of this program, luspatercept has been approved by the FDA for the treatment of lower-risk MDS in the first-line setting.
Real-World Data for Luspatercept in Lower-Risk MDS

Oct 12, 2023 | onclive.com | Uwe Platzbecker |Rami D. Komrokji |Valeria Santini

Matching-Adjusted Analysis Shows Acalabrutinib/Obinutuzumab Offers PFS Benefit Vs Zanubrutinib in CLL/SLL Without 17p DeletionsDr Brander on Findings From the TRANSCEND CLL 004 Trial in Relapsed/Refractory CLL/SLLDr Coombs on Switching to Treatment With a BCL-2 Inhibitor Vs a Covalent BTK Inhibitor in CLL/SLLAcalabrutinib Is Associated With Low Frequency of Cardiac Events Across 3 Randomized Trials in CLL
Clinical Implications of Recent Data on New Agents in Lower-Risk MDS

Oct 5, 2023 | onclive.com | Uwe Platzbecker |Rami D. Komrokji |Valeria Santini

Clinical Implications of Recent Data on New Agents in Lower-Risk MDSExpert perspectives on the clinical implications of recent clinical trial data on new therapies in lower-risk myelodysplastic syndrome.
Recent Updates for Second-Line Treatment Options in Lower-Risk MDS

Oct 5, 2023 | onclive.com | Uwe Platzbecker |Rami D. Komrokji |Valeria Santini
MEDALIST Trial: Luspatercept in Patients with Lower-Risk MDS

Sep 28, 2023 | onclive.com | Uwe Platzbecker |Rami D. Komrokji |Valeria Santini

At Multiple Dose Levels, Mezigdomide Elicits Responses in Combination With Bortezomib or Carfilzomib in R/R Myeloma
Lower-Risk MDS: How Do Practice Patterns Compare Worldwide?

Sep 28, 2023 | onclive.com | Uwe Platzbecker |Rami D. Komrokji |Valeria Santini

Comprehensive insights on the differences and similarities in treatment algorithms for physicians treating patients with MDS in and outside the United States. Please note: Since the filming of this program, luspatercept has been approved by the FDA for the treatment of lower-risk MDS in the first-line setting.
Long-term utilization and benefit of luspatercept in transfusion-dependent, erythropoiesis-stimulating agent-refractory or -intolerant patients with lower-risk myelodysplastic syndromes with ring sideroblasts | Leukemia

Sep 26, 2023 | nature.com | Uwe Platzbecker |Valeria Santini |Rami S. Komrokji |Guillermo Garcia-Manero

To the Editor:Myelodysplastic syndromes (MDS) are disorders of hematopoietic stem cells characterized by ineffective hematopoiesis, commonly leading to anemia [1]. The main goals in the treatment of lower-risk MDS (LR-MDS) are to manage anemia, improve or maintain quality of life (QoL), and delay disease progression to higher-risk MDS (HR-MDS) and acute myeloid leukemia (AML) [1, 2]. Chronic anemia in LR-MDS is associated with increased mortality and morbidity rates [3, 4].
Clinical Insights into the COMMANDS Trial

Sep 21, 2023 | onclive.com | Uwe Platzbecker |Rami D. Komrokji |Valeria Santini

The expert panel reviews updated data from the COMMANDS trial on luspatercept in patients with lower-risk MDS and discusses their effect on clinical practice. Please note: Since the filming of this program, luspatercept has been approved by the FDA for the treatment of lower-risk MDS in the first-line setting.